Plasma Glucagon-like Peptide-1 Levels and Acute Myocardial Infarction
Completed
- Conditions
- Glucagon-like Peptide-1Coronary Angiography
- Registration Number
- NCT03129594
- Lead Sponsor
- Chinese PLA General Hospital
- Brief Summary
GLP-1(9-36) amide and (9-37), which was previously thought to be the inactive metabolite of GLP-1, also exerts cardioprotective effects. Direct administration of GLP-1(9-36) during reperfusion reduced ischaemic damage in isolated hearts and increased cGMP release, vasodilatation and coronary flow in AMI mouse model, one may speculate that total GLP-1 level may associate with adverse cardiovascular events in AMI patients, the hypothesis is therefore tested in this study.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 709
Inclusion Criteria
- consecutive patients of acute AMI come to our department,absent of cardiogenic shock, and survival for at least 24 h after PCI treatment.
Exclusion Criteria
- patients with cancer, and patients who were taking a DPP4 inhibitor or a glucagon-like peptide-1 (GLP-1) analogue
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method all-cause mortality The median follow-up was 29 months cardiovascular mortality The median follow-up was 29 months
- Secondary Outcome Measures
Name Time Method non-cardiovascular mortality The median follow-up was 29 months Myocardial infarction The median follow-up was 29 months heart failure readmission The median follow-up was 29 months readmission to any hospital due to diagnosed heart failure
Stroke The median follow-up was 29 months defined using the World Health Organization criteria
repeated revascularization The median follow-up was 29 months defined as repeated PCI or bypass grafting of not only infarct related artery